FDA DEVICE FACTS
First Sign Multi-Drug Test Dip Card, First Sign Multi-Drug Test Cup, First Sign Multi-Drug Screen Test Dip Card, First Sign Multi-Drug Screen Test Cup
W.H.P.M., Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
First Sign Multi-Drug Test Dip Card is competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Buprenorphine, Butalbital, Oxazepam, Cocaine, 2-ethylidene-1,5-dimethyl -3,3-diphenylpyrrolidine, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Methadone, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline and Marijuana in human urine at the cutoff concentrations of: Drug(Identifier) Cut-off level Amphetamine (AMP) 1000ng/mL or 500 ng/mL Buprenorphine (BUP) 10 ng/mL Butalbital (BAR) 300 ng/mL Oxazepam (BZO) 300 ng/mL Cocaine (COC) 300ng/mL or 150 ng/mL 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine (EDDT) 300 ng/mL Methamphetamine (MET) 1000ng/mL or 500 ng/mL Methylenedioxy-methamphetamine (MDMA) 500 ng/mL Morphine (MOP 300/OPI 2000) 2000ng/mL or 300 ng/mL Methadone (MDT) 300 ng/mL Oxycodone (OXY) 100 ng/mL Phencyclidine (PCP) 25 ng/mL Propoxyphene (PPX) 300 ng/mL Nortriptyline (TCA) 1000 ng/mL Marijuana (THC) 50 ng/mL Configuration of the First Sign Multi-Drug Test Dip Card can consist of any combination of the above listed drug analytes. The test may yield positive results for the prescription drugs Buprenorphine, Oxazepam, Butalbital, Nortriptyline, Propoxyphene and Oxycodone w hen t aken at or above prescribed doses. It is not intended t o distinguish between prescription use or abuse of thes e drugs. Clinical consideration and professional judgment shoul d be exercised with any drug of abuse test result, particularly when the preliminary result is positive. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/ MS or LC/M S is the preferred confirmator y method. For in vitro diagnostic use only. First Sign Multi-Drug Test Cup is competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Buprenorphine, Butalbital, Oxazepam, Cocaine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Methadone, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline and Marijuana i n human urine at the cutoff concentrations of: Drug(Identifier) Cut-off level Amphetamine (AMP) 1000ng/mL or 500 ng/mL Buprenorphine (BUP) 10 ng/mL Butalbital (BAR) 300 ng/mL Oxazepam (BZO) 300 ng/mL Cocaine (COC) 300ng/mL or 150 ng/mL 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine (EDDT) 300 ng/mL Methamphetamine (MET) 1000ng/mL or 500 ng/mL Methylenedioxy-methamphetamine (MDMA) 500 ng/mL Morphine (MOP 300/OPI 2000) 2000ng/mL or 300 ng/mL Methadone (MDT) 300 ng/mL Oxycodone (OXY) 100 ng/mL Phencyclidine (PCP) 25 ng/mL Propoxyphene (PPX) 300 ng/mL Nortriptyline (TCA) 1000 ng/mL Marijuana (THC) 50 ng/mL Configuration of the First Sign Multi-Drug Test Cup can consist of any combination of the above listed drug analytes. The test may yield positive results for the prescription drugs Buprenorphine, Oxazepam, Butalbital, Nortriptyline, Propoxyphene and Oxycodone when t aken at or above prescribed doses. It is not intended t o distinguish between prescription use or abuse of these drugs. Clinical consideration and professional judgment shoul d be exercised with any drug of abuse test result, particularly when the preliminary result is positive. T he test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/ MS or LC/M S is the preferred confirmator y method. For in vitro diagnostic use only. First Sign Multi-Drug Screen Test Dip Card is competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Buprenorphine, Butalbital, Oxazepam, Cocaine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Methadone, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline and Marijuana in human urine at the cutoff concentrations of: Drug(Identifier) Cut-off level Amphetamine (AMP) 1000ng/mL or 500 ng/mL Buprenorphine (BUP) 10 ng/mL Butalbital (BAR) 300 ng/mL Oxazepam (BZO) 300 ng/mL Cocaine (COC) 300ng/mL or 150 ng/mL 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine (EDDT) 300 ng/mL Methamphetamine (MET) 1000ng/mL or 500 ng/mL Methylenedioxy-methamphetamine (MDMA) 500 ng/mL Morphine (MOP 300/OPI 2000) 2000ng/mL or 300 ng/mL Methadone (MDT) 300 ng/mL Oxycodone (OXY) 100 ng/mL Phencyclidine (PCP) 25 ng/mL Propoxyphene (PPX) 300 ng/mL Nortriptyline (TCA) 1000 ng/mL Marijuana (THC) 50 ng/mL Configuration of the First Sign Multi-Drug Screen Test Dip Card can consist of any combination of the above listed drug analytes. The test may yield positive results for the prescription drugs Buprenorphine, Oxazepam, Butalbital, Nortriptyline, Propoxyphene and Oxycodone when taken at or above prescribed doses. It is not intended to distinguish between prescripti on use or abuse of thes e drugs. Clinical consideration and professional judgment shoul d be exercised with any drug of abuse test result, particularly w hen the preliminary result is positive. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/ MS or LC/M S is the preferred confirmator y method. For in vitro diagnostic use only. It is for prescripti on use. First Sign Multi-Drug Screen Test Cup is competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Buprenorphine, Butalbita l, Oxazepam, Cocaine, 2-ethylidene -1,5-dimethyl -3,3-diphenylpyrrolidine, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Methadone, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline and Marijuana in human urine at the cutoff concentrations of: Drug(Identifier) Cut-off level Amphetamine (AMP) 1000ng/mL or 500 ng/mL Buprenorphine (BUP) 10 ng/mL Butalbital (BAR) 300 ng/mL Oxazepam (BZO) 300 ng/mL Cocaine (COC) 300ng/mL or 150 ng/mL 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine (EDDT) 300 ng/mL Methamphetamine (MET) 1000ng/mL or 500 ng/mL Methylenedioxy-methamphetamine (MDMA) 500 ng/mL Morphine (MOP 300/OPI 2000) 2000ng/mL or 300 ng/mL Methadone (MDT) 300 ng/mL Oxycodone (OXY) 100 ng/mL Phencyclidine (PCP) 25 ng/mL Propoxyphene (PPX) 300 ng/mL Nortriptyline (TCA) 1000 ng/mL Marijuana (THC) 50 ng/mL Configuration of the First Sign Multi-Drug Screen Test Cup can consist of any combination of the above listed drug analytes. The test may yield positive results for the prescription drugs Buprenorphine, Oxazepam, Butalbital, Nortriptyline, Propoxyphene and Oxycodone when taken at or above prescribed doses. It is not intended to distinguish between prescription use or abuse of these drugs. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/ MS or LC/MS is the preferred confirmatory method. For in vitro diagnostic use only. It is for prescription use.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。